Limits...
Effective dosage and administration schedule of oral alendronate for non-nociceptive symptoms in rats with chronic constriction injury.

Im S, Lim SH, Lee JI, Ko YJ, Park JH, Hong BY, Park GY - J. Korean Med. Sci. (2010)

Bottom Line: On the 14th day post-CCI, the HE group showed significant reduction in thickness and temperature (P<0.001).On the 42nd day post-CCI, the HE group showed significant reduction in temperature compared to the NT group (P<0.001).Also, both HE and HL groups showed statistically significant increased tibia BMD (P<0.001), along with increase of tibia bone strength compared to the NT group.

View Article: PubMed Central - PubMed

Affiliation: Department of Rehabilitation Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.

ABSTRACT
We evaluated the efficacy of oral alendronate with different dosing regimens for non-nociceptive symptoms and osteoporosis in a sciatic nerve chronic constriction injury (CCI) model. Male Sprague-Dawley rats (n=60) were subdivided into sham control (SC) group and CCI groups, which were divided according to dosage and time of oral alendronate administration: no treatment (NT), low dosage early (LE), high dosage early (HE), low dosage late (LL) and high dosage late (HL). We measured the thickness and temperature of the hind paw, bone mineral density (BMD) of the tibia, along with tibia bone strength. On the 14th day post-CCI, the HE group showed significant reduction in thickness and temperature (P<0.001). On the 42nd day post-CCI, the HE group showed significant reduction in temperature compared to the NT group (P<0.001). Also, both HE and HL groups showed statistically significant increased tibia BMD (P<0.001), along with increase of tibia bone strength compared to the NT group. Based on these findings, early alendronate in high dosages is effective in the non-nociceptive symptoms; early and late alendronate in high dosages, are effective in preventing bone dystrophic changes in a CCI model.

Show MeSH

Related in: MedlinePlus

Efficacy of oral alendronate in different dosage and time of administration in dorsal-ventral thicknesses of the affected hind-paw from Sprague-Dawley rats.*P<0.001 as compared with NT group; †P<0.001 as compared with SC group.CCI, chronic constriction injury; SC, sham control; NT, no treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2877239&req=5

Figure 1: Efficacy of oral alendronate in different dosage and time of administration in dorsal-ventral thicknesses of the affected hind-paw from Sprague-Dawley rats.*P<0.001 as compared with NT group; †P<0.001 as compared with SC group.CCI, chronic constriction injury; SC, sham control; NT, no treatment.

Mentions: Prior to CCI, no significant differences of hindpaw thickness were detected between groups (Fig. 1). Fourteen days after CCI, the thicknesses of the hind paws for 5 CCI groups were significantly thicker than that of the SC group. Thicknesses for the HE and SC group were significantly reduced than that of the NT group (P<0.001). Forty two days after CCI, only the SC group showed significantly reduced thickness than that of the NT group. Also, thicknesses of hind paws for the 2 low dosage treatment (LE and LL) groups and NT were significantly thicker than that of the SC group. The 2 high dosage groups (HE, HL) did not show statistically significant difference of thickness (Table 1) in comparison to NT group.


Effective dosage and administration schedule of oral alendronate for non-nociceptive symptoms in rats with chronic constriction injury.

Im S, Lim SH, Lee JI, Ko YJ, Park JH, Hong BY, Park GY - J. Korean Med. Sci. (2010)

Efficacy of oral alendronate in different dosage and time of administration in dorsal-ventral thicknesses of the affected hind-paw from Sprague-Dawley rats.*P<0.001 as compared with NT group; †P<0.001 as compared with SC group.CCI, chronic constriction injury; SC, sham control; NT, no treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2877239&req=5

Figure 1: Efficacy of oral alendronate in different dosage and time of administration in dorsal-ventral thicknesses of the affected hind-paw from Sprague-Dawley rats.*P<0.001 as compared with NT group; †P<0.001 as compared with SC group.CCI, chronic constriction injury; SC, sham control; NT, no treatment.
Mentions: Prior to CCI, no significant differences of hindpaw thickness were detected between groups (Fig. 1). Fourteen days after CCI, the thicknesses of the hind paws for 5 CCI groups were significantly thicker than that of the SC group. Thicknesses for the HE and SC group were significantly reduced than that of the NT group (P<0.001). Forty two days after CCI, only the SC group showed significantly reduced thickness than that of the NT group. Also, thicknesses of hind paws for the 2 low dosage treatment (LE and LL) groups and NT were significantly thicker than that of the SC group. The 2 high dosage groups (HE, HL) did not show statistically significant difference of thickness (Table 1) in comparison to NT group.

Bottom Line: On the 14th day post-CCI, the HE group showed significant reduction in thickness and temperature (P<0.001).On the 42nd day post-CCI, the HE group showed significant reduction in temperature compared to the NT group (P<0.001).Also, both HE and HL groups showed statistically significant increased tibia BMD (P<0.001), along with increase of tibia bone strength compared to the NT group.

View Article: PubMed Central - PubMed

Affiliation: Department of Rehabilitation Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.

ABSTRACT
We evaluated the efficacy of oral alendronate with different dosing regimens for non-nociceptive symptoms and osteoporosis in a sciatic nerve chronic constriction injury (CCI) model. Male Sprague-Dawley rats (n=60) were subdivided into sham control (SC) group and CCI groups, which were divided according to dosage and time of oral alendronate administration: no treatment (NT), low dosage early (LE), high dosage early (HE), low dosage late (LL) and high dosage late (HL). We measured the thickness and temperature of the hind paw, bone mineral density (BMD) of the tibia, along with tibia bone strength. On the 14th day post-CCI, the HE group showed significant reduction in thickness and temperature (P<0.001). On the 42nd day post-CCI, the HE group showed significant reduction in temperature compared to the NT group (P<0.001). Also, both HE and HL groups showed statistically significant increased tibia BMD (P<0.001), along with increase of tibia bone strength compared to the NT group. Based on these findings, early alendronate in high dosages is effective in the non-nociceptive symptoms; early and late alendronate in high dosages, are effective in preventing bone dystrophic changes in a CCI model.

Show MeSH
Related in: MedlinePlus